181 related articles for article (PubMed ID: 38168220)
1. Facile generation of biepitopic antibodies with intrinsic agonism for activating receptors in the tumor necrosis factor superfamily.
Jhajj HS; Schardt JS; Khalasawi N; Yao EL; Lwo TS; Kwon NY; O'Meara RL; Desai AA; Tessier PM
bioRxiv; 2023 Dec; ():. PubMed ID: 38168220
[TBL] [Abstract][Full Text] [Related]
2. Facile generation of biepitopic antibodies with intrinsic agonism for activating tumor necrosis factor receptors.
Jhajj HS; Schardt JS; Khalasawi N; Yao EL; Lwo TS; Kwon NY; O'Meara RL; Desai AA; Tessier PM
Cell Chem Biol; 2024 May; 31(5):944-954.e5. PubMed ID: 38653243
[TBL] [Abstract][Full Text] [Related]
3. Tetravalent biepitopic targeting enables intrinsic antibody agonism of tumor necrosis factor receptor superfamily members.
Yang Y; Yeh SH; Madireddi S; Matochko WL; Gu C; Pacheco Sanchez P; Ultsch M; De Leon Boenig G; Harris SF; Leonard B; Scales SJ; Zhu JW; Christensen E; Hang JQ; Brezski RJ; Marsters S; Ashkenazi A; Sukumaran S; Chiu H; Cubas R; Kim JM; Lazar GA
MAbs; 2019; 11(6):996-1011. PubMed ID: 31156033
[TBL] [Abstract][Full Text] [Related]
4. Unlocking the potential of agonist antibodies for treating cancer using antibody engineering.
Jhajj HS; Lwo TS; Yao EL; Tessier PM
Trends Mol Med; 2023 Jan; 29(1):48-60. PubMed ID: 36344331
[TBL] [Abstract][Full Text] [Related]
5. FcγRII-binding Centyrins mediate agonism and antibody-dependent cellular phagocytosis when fused to an anti-OX40 antibody.
Zhang D; Whitaker B; Derebe MG; Chiu ML
MAbs; 2018 Apr; 10(3):463-475. PubMed ID: 29359992
[TBL] [Abstract][Full Text] [Related]
6. CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement.
Gaspar M; Pravin J; Rodrigues L; Uhlenbroich S; Everett KL; Wollerton F; Morrow M; Tuna M; Brewis N
Cancer Immunol Res; 2020 Jun; 8(6):781-793. PubMed ID: 32273279
[TBL] [Abstract][Full Text] [Related]
7. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.
Zhang D; Goldberg MV; Chiu ML
J Biol Chem; 2016 Dec; 291(53):27134-27146. PubMed ID: 27856634
[TBL] [Abstract][Full Text] [Related]
8. The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy.
Claus C; Ferrara-Koller C; Klein C
MAbs; 2023; 15(1):2167189. PubMed ID: 36727218
[TBL] [Abstract][Full Text] [Related]
9. Basic characterization of antibodies targeting receptors of the tumor necrosis factor receptor superfamily.
Zaitseva O; Anany M; Wajant H; Lang I
Front Immunol; 2023; 14():1115667. PubMed ID: 37051245
[TBL] [Abstract][Full Text] [Related]
10. Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists.
Fromm G; de Silva S; Schreiber TH
Front Immunol; 2023; 14():1236332. PubMed ID: 37795079
[TBL] [Abstract][Full Text] [Related]
11. 4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB.
Arch RH; Thompson CB
Mol Cell Biol; 1998 Jan; 18(1):558-65. PubMed ID: 9418902
[TBL] [Abstract][Full Text] [Related]
12. Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity.
Ho SK; Xu Z; Thakur A; Fox M; Tan SS; DiGiammarino E; Zhou L; Sho M; Cairns B; Zhao V; Xiong M; Samayoa J; Forsyth CM; Powers DB; Chao DT; Hollenbaugh D; Alvarez HM; Akamatsu Y
Mol Cancer Ther; 2020 Apr; 19(4):1040-1051. PubMed ID: 31974274
[TBL] [Abstract][Full Text] [Related]
13. ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1.
Enell Smith K; Fritzell S; Nilsson A; Barchan K; Rosén A; Schultz L; Varas L; Säll A; Rose N; Håkansson M; von Schantz L; Ellmark P
Cancer Immunol Immunother; 2023 Dec; 72(12):4145-4159. PubMed ID: 37796298
[TBL] [Abstract][Full Text] [Related]
14. Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist.
Upadhyaya P; Lahdenranta J; Hurov K; Battula S; Dods R; Haines E; Kleyman M; Kristensson J; Kublin J; Lani R; Ma J; Mudd G; Repash E; Van Rietschoten K; Stephen T; You F; Harrison H; Chen L; McDonnell K; Brandish P; Keen N
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33500260
[TBL] [Abstract][Full Text] [Related]
15. Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.
Waight JD; Gombos RB; Wilson NS
Hum Antibodies; 2017; 25(3-4):87-109. PubMed ID: 28085016
[TBL] [Abstract][Full Text] [Related]
16. Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization.
Zhang D; Armstrong AA; Tam SH; McCarthy SG; Luo J; Gilliland GL; Chiu ML
MAbs; 2017 Oct; 9(7):1129-1142. PubMed ID: 28758875
[TBL] [Abstract][Full Text] [Related]
17. Analysis of FcγR-Dependent Agonism of Antibodies Specific for Receptors of the Tumor Necrosis Factor (TNF) Receptor Superfamily (TNFRSF).
Medler J; Wajant H
Methods Mol Biol; 2021; 2248():81-90. PubMed ID: 33185869
[TBL] [Abstract][Full Text] [Related]
18. Expeditious Generation of Biparatopic Common Light Chain Antibodies
Bogen JP; Carrara SC; Fiebig D; Grzeschik J; Hock B; Kolmar H
Front Immunol; 2020; 11():606878. PubMed ID: 33424853
[TBL] [Abstract][Full Text] [Related]
19. Tight nanoscale clustering of Fcγ receptors using DNA origami promotes phagocytosis.
Kern N; Dong R; Douglas SM; Vale RD; Morrissey MA
Elife; 2021 Jun; 10():. PubMed ID: 34080973
[TBL] [Abstract][Full Text] [Related]
20. Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy.
Liu G; Luo P
Front Immunol; 2023; 14():1208788. PubMed ID: 37334375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
